PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|March 9, 2016
BioPhorum Operations Group Invites Industry Stakeholders to Participate in Technology Roadmap
Author(s)Pharmaceutical Technology Editors
The group is inviting additional industry stakeholders to participate in the technology roadmapping process to address complexity of the current industry structure, which the group says has held back innovation.
Advertisement
The BioPhorum Operations Group is inviting industry stakeholders including academics, supply partner R&D heads, regulators, and regional hubs to participate in the group’s Technology Roadmap for the future of biopharmaceuticals. The Technology Roadmap is being developed in response to the complexity of the current industry structure, which the group says has held back innovation with many end users trying to develop new technologies in isolation, and resulting in suppliers having to guess end user requirements. The group currently has more than 100 active participants in the roadmapping process, consisting of a steering committee and six teams working to address key technology challenges.
Eighteen BioPhorum member companies are currently developing the roadmap, and the group is hoping to add additional participants to the project. When complete, the Technology Roadmap will be available for free and updated and published on a regular basis.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement